Wockhardt Ltd. has secured approval from India's Central Drugs Standard Control Organisation (CDSCO) to market Zaynich (Zidebactam/Cefepime), a novel antibiotic developed to combat a range of severe drug-resistant infections. This significant regulatory clearance marks a new addition to the company's anti-infectives portfolio, offering a vital treatment alternative amidst growing concerns over antimicrobial resistance.
Zaynich is specifically indicated for treating complicated urinary tract infections, including kidney infections, and cases where the infection has spread to the bloodstream. The antibiotic is designed to target challenging Gram-negative bacteria, which are a leading cause of hospital-acquired infections, particularly those exhibiting metallo-beta-lactamase (MBL) mechanisms—a resistance pathway that renders many existing antibiotics ineffective.
Clinical Efficacy Demonstrated in Trials
The approval is underpinned by robust data from the Phase III ENHANCE-1 study, which compared Zaynich against meropenem, a commonly used antibiotic for severe infections. Wockhardt reported that 89% of patients treated with Zaynich achieved both clinical recovery and clearance of the infection, significantly outperforming meropenem, which showed a 68.4% success rate. These positive outcomes were observed approximately ten days post-treatment.
Furthermore, Zaynich demonstrated superior efficacy in patients with bloodstream infections. In this critical subgroup, 89% of those receiving Zaynich responded to treatment, compared to only 44% in the meropenem arm. These findings underscore the drug's potential in managing more severe and life-threatening infections.
Broader Development and Global Aspirations
Prior to the Phase III trial, Zaynich underwent extensive evaluation, including nine Phase I trials and a Phase II study. The Phase II study, conducted across 15 tertiary care hospitals in India, reported clinical efficacy exceeding 97% for conditions such as hospital-acquired pneumonia, abdominal infections, and complicated urinary tract infections, in addition to bloodstream infections.
Wockhardt highlighted that existing treatment options for some resistant infections are often limited by side effects and reduced effectiveness. Zaynich aims to provide a much-needed alternative. The therapy has already been utilized in 85 patients with highly drug-resistant infections across India, the United States, Malaysia, and France under compassionate-use programs where no other suitable treatments were available.
While India marks the first regulatory clearance, Wockhardt has also submitted applications for approval in the United States and the European Union, where reviews are currently underway. The U.S. Food and Drug Administration (FDA) has granted Zaynich several key designations, including Priority Review, Fast Track, and Qualified Infectious Disease Product (QIDP) status for multiple infection categories, signaling its potential importance in global public health. This new approval strengthens Wockhardt's commitment to combating infectious diseases, with six other antibiotic programs in various stages of development targeting both Gram-negative and Gram-positive bacteria.